Sweden - Carl-David Agardh intervju p� Diabetesportalen

Wed, 10 Sep 2008 06:14:19

GAD-vaccinet verksamt �nnu efter fem �r Resultaten fem �r efter GAD-vaccinationen visar att patienterna fortfarande har en b�ttre bevarad egen insulinproduktion och att f�rre tvingats b�rja med insulinsprutor. I den f�rsta unders�kningen med GAD-vaccinationer behandlades 47 vuxna patienter med LADA-diabetes, den speciella form av typ 2 diabetes som drabbar vuxna men som i likhet med typ 1 diabetes beror p� att kroppens eget immunf�rsvar angriper och f�rst�r de insulinproducerande cellerna. P� sikt blir LADA-patienter beroende av insulininjektioner. M�let med GAD-vaccinet �r att om m�jligt bromsa eller helt stoppa det autoimmuna angreppet som d�dar de insulinproducerande betacellerna. L�s hela artikeln

Sweden - Samlade notiser fr�n svenska nyhetsbyr�er

Wed, 03 Sep 2008 09:33:43

Samlade notiser fr�n svenska nyhetsbyr�er efter Financial Hearings p� Operaterassen 2 september 2008.

Diamyd Medical: F�rsta rapport rekrytering fas-3 om 1 m�n

Diamyd Medical: Upprepat fas-2-res i fas-3 ger FDA-godk�nnande

DIAMYD MEDICAL: R�KNAR MED LICENSAVTAL NTDDS-TEKNIKEN 2009

DIAMYD MEDICAL:F�RSTA RES REKRYTERING FAS III INOM 1...

Sweden - Biotech Sweden writes about Diamyd.

Mon, 01 Sep 2008 16:24:28

Biotech Sweden writes about Diamyd's new technology against diabetes pain.

Read the whole article here

Sweden - Di.se skriver om bioteknik: "Det finns guldkorn inom biotekniken"

Thu, 28 Aug 2008 14:46:31

Stefan Wikholm fr�n Redeye skriver idag p� di.se om bioteknik branschen. "B�rsen i dag: Det finns guldkorn inom biotekniken"

L�s hela artikeln

Sweden - Diamyd-aktien listas bland Aff�rsv�rldens l�sarkrets favoritaktie.

Wed, 27 Aug 2008 11:02:52

L�sarnas egna favoritaktier

Aktietipsen fr�n Aff�rsv�rldens l�sare har b�rjat str�mma in.
Signaturen PGVInvest rekommenderar k�p i forskningsbolagen Diamyd Medical och Karo Bio. Det f�rstn�mnda har ett intressant preparat p� g�ng mot diabetes.

L�s hela artikeln h�r

Sweden - Nyhetsnotis om Diamyd i Aff�rsv�rlden - Allt g�r enligt plan med fas-III studie

Tue, 26 Aug 2008 11:34:59

Diamyd Medicals studie med Diamyd f�r behandling av diabetes av typ-1 fortg�r som planerat. Bolaget
h�ller fast vid den tidigare uppgivna tidsplanen, som inneb�r de v�ntar sig kunna se studieresultaten under h�sten 2010 med sista patient rekryterad till studien vid mitten av 2009.

"Det jag kan s�ga �r att allting g�r enligt plan och det �r inga konstigheter n�gonstans", sade Diamyd Medicals VD Elisabeth Lindner under bolagets tr�ff med investerare och forts�tter "vi har satt som m�ls�ttning att g� v�ldigt brett med m�nga kliniker s� att vi �r s�kra p� att komma i hamn med sista rekryterad patient (last patient in)".

Diamyd har fattat ett beslut om att redovisa rekryteringen blockvis d� vissa f�rutbest�mda andelar av den totala m�ngden som ska rekryteras.

...

Sweden - Nyhetsnotis om Diamyd i Aff�rsv�rlden - planerar NTDDS-studie fas-I/II under 2009

Tue, 26 Aug 2008 11:32:02

Diamyd Medical planerar under 2009 att genom sitt amerikanska dotterbolag inleda en studie inom NTDDS med GAD mot diabetessm�rta i fas-I/II. Genom att d� redan ha f�rdigst�llt en doseskaleringsstudie i fas-I med NP2 omfattande 12 cancerpatienter bed�mer Darren Wolfe, VD f�r Diamyd Medicals amerikanska dotterbolag Diamyd, att bolaget har vunnit upp till tolv m�nader �n gentemot om Diamyd Medical hade valt att
genomf�ra tv� separata studier i fas-I och fas-II mot diabetessm�rta.

L�s hela artikeln h�r

Sweden - Nyhetsnotis om Diamyd i Aff�rsv�rlden - Ber�knad burnrate 4,5 Mkr per m�n 2008

Tue, 26 Aug 2008 11:28:31

Diamyd uppger sig ha gjort framsteg i de p�g�ende
partnerskapsdiskussionerna sedan i somras och m�let �r att
senast vid mitten av 2009 ha tecknat ett avtal.
"Vi vet ju inte om det kan bli tidigare, men man ska inte
underskatta tiden till man har formaliserat ett avtal, s� att
senast 2009", s�ger Lindner.

L�s hela artikeln h�r

Sweden - Biotech Scandinavia writes about Diamyd.

Thu, 21 Aug 2008 09:49:57

Biotech Scandinavia writes about Diamyd and the GAD Phase II trials conducted by Neurologix.

Read the article here

Sweden - Aff�rsv�rlden har publicerat flera notiser om Diamyd

Thu, 21 Aug 2008 09:45:44

Onsdagen den 20 augusti har Aff�rsv�rlden publicerat fyra nyhetsbyr� notiser om Diamyd

L�s notis ett h�r
L�s notis tv� h�r
L�s notis tre h�r
L�s notis fyra h�r

USA - The BioWorld Today ranks Diamyd� Monday 18th of August

Tue, 19 Aug 2008 11:36:44

The BioWorld Diabetes report 2008 ranks Diamyd as one of the top Diabetes Drugs in Development to Watch.

Sweden - Dagens Industri skriver om starkt �r f�r biotekniksektorn.

Tue, 12 Aug 2008 14:03:16

I dagens DI skriver kr�nik�ren Cecilia Johansson om biotekniksektorn under rubriken "Starkt �r f�r sv�ngig sektor" och anser det vara rimligt att Diamyd Medicals �r bland de h�gst v�rderade i gruppen, med tanke p� marknadspotentialen.

Sweden - Vaccinet Diamyd� positioneras i tv� olika produkter; en f�r typ 1-diabetes och en separat produkt f�r LADA. Detta efter att 5-�rs data publiceras.

Tue, 12 Aug 2008 10:14:46

Resultat fr�n Diamyd Medicals studie visar att vaccination med Diamyd, fortfarande efter 5 �r, signifikant minskar risken f�r att patienter med LADA (Latent Autoimmune Diabetes in Adult) beh�ver insulinbehandling.

L�s hela artikeln h�r
L�s hela pressmeddelandet h�r

Sweden - Diamyds VD och koncernchef Elisabeth Lindner intervjuad i Dagens Nyheter Ekonomi m�ndag 7 juli 2008.

Mon, 07 Jul 2008 12:18:02

Diamyds VD och koncernchef Elisabeth Lindner intervjuad i Dagens Nyheter Ekonomi, i samband med att en unders�kning utf�rd av forskaren Monica Renstig p� Womens Business Research Institute, avsl�jar att andelen kvinnliga chefer i n�ringslivet har slutat �ka. Dock har andelen kvinnor i svenska f�retagsledningar �kat med en procentenhet till 13,5% enligt samtliga �rsredovisningar f�r 2007.

Diamyd ligger i topp p� listan �ver b�rsf�retag med h�gst andel kvinnor i ledningen.

Sweden - Dagens Industri skriver om kvinnliga chefer i b�rsbolag. Diamyd ligger i topp.

Mon, 07 Jul 2008 11:43:47

Allra flest kvinnliga chefer har l�kemedelsbolaget Diamyd, skriver Dagens Industri.

L�s artikeln om kvinnliga chefer h�r

Sweden - Dagens Medicin har publicerat artikel med Professor Johnny Ludvigsson, huvudpr�vare i Diamyd� fas III europeiska studie.

Mon, 07 Jul 2008 11:34:18

Sanningens �gonblick n�rmar sig f�r svensk vaccinkandidat.

L�s hela artikeln h�r.

Sweden - B�ttre chans �n n�gonsin att l�sa diabetesg�tan - Intervju med �ke Lennmark publicerad p� diabetesportalen

Thu, 03 Jul 2008 12:30:34

En l�ng intervju med �ke Lennmark, medlem i Diamyds Medical Advisory Board, har publicerats p� Diabetesportalen. �ke Lernmark har �gnat hela sin forskarkarri�r �t typ 1-diabetes.
L�s hela artikeln h�r.

USA - Diamyd Medicals CEO Mrs Elisabeth Lindner in webcast interview for World Business Broadcast.

Tue, 24 Jun 2008 13:19:15

Mr Todd Santorelli, journalist for O Six Media has interviewed Mrs Elisabeth Lindner in June 2008.

Listen to the webcast by clicking on the link "interview" from the homepage http://www.osixmedia.com

Sweden - Barndiabetesfonden n�mner Diamyds Fas III studie p� sin f�rsta sida

Wed, 11 Jun 2008 12:49:00

Barndiabetesfonden skriver p� sin hemsida:

Genombrott f�r diabetesvaccin
L�kemedelsf�retaget Diamyd har nu beg�rd att f� g� in i fas 3-studie av diabetesvaccinet Diamyd. Effekten av l�kemedlet har visat sig ge ett l�ngsiktigt skydd vid de prov och tester som hittills utf�rts.

Sweden - Nyhetsnotis om m�jlighet att s�rl�kemedelsklassa Diamyd�

Wed, 11 Jun 2008 12:01:00

Diamyd Medical: M�jlighet att s�rl�kemedelsklassa Diamyd - VD

2008-06-10 15:51: K�lla: Nyhetsbyr�n SIX

http://www.affarsvarlden.se/hem/nyheter/article367887.ece

Sweden - Nyhetsnotis om potentiella partnerdiskussioner

Wed, 11 Jun 2008 01:02:00

Diamyd Medical: Flertal partnerdisk om st�rre avtal ig�ng - VD 2008-06-10 16:01: K�lla: Nyhetsbyr�n SIX http://www.affarsvarlden.se/hem/nyheter/article367909.ece

Sweden - Nyhetsnotis om Diamyds finansiering

Wed, 11 Jun 2008 01:00:00

Diamyd Medical: Befintliga medel plus option r�cker till h�sten -10 - VD

2008-06-10 15:56: K�lla: Nyhetsbyr�n SIX http://www.affarsvarlden.se/hem/nyheter/article367900.ece

Sweden - Nyhetsnotis om intresse fr�n omv�rlden f�r Diamyd�

Tue, 10 Jun 2008 12:55:00

Diamyd Medical: �kat intresse fr�n Sydamerika, Australien, Asien
2008-06-09 09:41: K�lla: Nyhetsbyr�n SIX

http://www.affarsvarlden.se/hem/nyheter/article366854.ece

Sweden - "Om tre �r kan diabetesvaccinet vara h�r" - skriver Svenska Dagbladet N�ringsliv p� f�rsta sidan.

Wed, 04 Jun 2008 09:28:00

"Om tre �r kan diabetesvaccinet vara h�r" - skriver Svenska Dagbladet N�ringsliv p� f�rsta sidan idag 4 juni 2008. P� sidan 24 f�ljer en "5 fr�gor"-intervju med Diamyds VD och koncernchef Elisabeth Lindner.

Sweden - Intervju med Elisabeth Lindner, p� placera.nu "Vi st�r inf�r ett genombrott"

Wed, 04 Jun 2008 01:17:00

Intervju med Diamyds VD och koncernchef, Elisabeth Lindner - "Vi st�r inf�r ett genombrott" L�s hela artikeln p� www.placera.nu

USA - Technology Review writes about Diamyd NTDDS platform

Wed, 14 May 2008 14:27:00

Extract from article in Technology Review The Stockholm-based company Diamyd Medical has been developing a different approach to gene therapy for chronic pain that also bypasses the side effects of standard pain treatment. The approach uses a deactivated version of herpes simplex virus (HSV). HSV can be administered straight through the skin as it naturally finds and infects peripheral nerves and travels to the spinal cord on its own. Darren Wolfe of Diamyd says that this method is superior to spinal injection because it's safer and easier, and it can be administered repeatedly.

Sweden - Further Boost For Swedish Diabetes Research. Stockholm Business Region Life Science News writes about Diamyd.

Mon, 12 May 2008 11:30:00

Further Boost For Swedish Diabetes Research The American National Institute of Health (NIH) is investing 130 -150 million Swedish kronor in Phase II clinical tests using Stockholm based Diamyd Medical�s therapeutic diabetic vaccine, Diamyd. The vaccine will be tested on 126 patients in America over a two-year period. The results of these tests, conducted by TrialNet, will be made available to Diamyd Medical. This interest by NIH is further confirmation of the potential of the vaccine. Following the positive results in a Phase II clinical trial in recent onset type 1 diabetes patients in Sweden, Diamyd Medical has been given approval to begin Phase III studies with Diamyd by the Swedish Medical Products Agency (MPA). The American Food and Drug Administration (FDA), has also given the compa...

USA - BioWorld International publish interview with Diamyd CEO Elisabeth Lindner.

Mon, 28 Apr 2008 09:14:00

BioWorld International publish interview with Diamyd CEO Elisabeth Lindner. Interview revolves around Phase III clinical trial and the direct placed placement of shares executed last week.

USA - Picture from Times Square, New York, Monday April 21st 2008. Diamyd CEO Elisabeth Lindner.

Thu, 24 Apr 2008 11:08:00

Picture from Times Square , New York, Monday April 21st 2008.

Diamyd CEO Elisabeth Lindner.

Germany - Diamyd mentioned in German media after publishing press release on strengthened financial position and executed fully subscribed direct placement.

Wed, 23 Apr 2008 11:07:00

Diamyd st�rkt finanzielle Position und f�hrt eine voll gezeichnete, direkte Platzierung durch Stockholm (ots/PRNewswire) - Diamyd Medical AB (publ) hat sich zu einer direkten Platzierung von insgeesamt 991.000 Aktien der Seri B entschlossen und diese erfolgreich durchgef�hrt. Die Aktien wurden bei einer begrenzten Gruppe von professionellen Investoren zu einem Preis von 73 SEK pro Aktie platziert. Die Emission erbringt f�r das Unternehmen vor Emissionskosten insgesamt 72,3 Mio. SEK. F�r jede ausgegebene und bezahlte neue Aktie erh�lt man kostenlos einen Optionsschein, mit dem man das Recht hat, im April 2009 eine Aktie der Serie B zum Preis von 100 SEK zu zeichnen. Die volle Nutzung der ausgegebenen Optionsscheine wird zus�tzlich 99,1 Mio. SEK an Erl�sen f�r das Unternehmen erbringen.

Sweden - Dagens Industri har noterat Diamyds kvartalsrapport i dagens papperstidning.

Wed, 23 Apr 2008 11:04:00

Diamyd publicerade kvartalsrapport den 22 april 2008. Dagens Industri n�mner resultaten i papperstidningen den 23 april 2008.

Sweden - Diamyd omn�mnt i Dagens Industri pappersbilaga 22 april 2008.

Tue, 22 Apr 2008 11:07:00

Diamyds VD och koncernchef Elisabeth Lindner har uttalat sig i Dagens Industri 22 april 2008 ang�ende nya institutionella �gare efter den riktade emissionen.

Sweden - DI.se citerar VD-ordet fr�n senaste kvartalsrapporten

Tue, 22 Apr 2008 11:00:00

Diamyd Medical: 5-�rsdata fas-II LADA inom n�rmaste m�naderna Bioteknikf�retaget Diamyd Medical kommer inom de n�rmaste m�naderna att f� in 5-�rsuppf�ljningsdata fr�n den f�rsta fas-II studien med 47 LADA-patienter. Det framg�r av uppgifter i rapporten. "Vi �r sp�nda p� att sammanst�lla denna data och se resultatet", skriver Diamyd Medicals VD Elisabeth Lindner i VD-kommentaren i rapporten.

France - Diamyd mentioned in French media after publishing press release on strengthened financial position and executed fully subscribed direct placement.

Mon, 21 Apr 2008 10:28:00

From French media: Diamyd consolide sa situation financi�re et excute un placement direct enti�rement souscrit Boursica.com le 21-04-2008 � 21h43 Diamyd consolide sa situation financi�re et excute un placement direct enti�rement souscrit STOCKHOLM, Su�de, April 21 /PRNewswire/ -- Diamyd Medical AB (publ) a pris la dcision et a effectu avec succ�s un placement direct totalisant 991 000 actions de srie B. Ces titres ont t vendus � un groupe limit d'investisseurs professionnels � un prix de 73 couronnes sudoises (SEK) l'action. Ainsi, l'mission s'l�ve � un total pour la socit de 72,3 millions de couronnes sudoises, excluant les frais d'mission. Pour chaque nouvelle action mise et paye, le titulaire recevra un bon de souscription gratuit lui confrant le droit de souscrire une act...

USA - Reuters Significant Developments: Biotechnology

Mon, 21 Apr 2008 10:22:00

Diamyd Medical AB Executes Direct Placement of 991,000 B Shares Monday, 21 Apr 2008 04:50am EDT Diamyd Medical AB announced that it has executed a direct placement of 991,000 B shares. The shares have been placed at a price of SEK 73 per share. For each issued and paid new share an equal number of warrants is received free of charge, which gives its holder the right to purchase additional B shares at a price of SEK 100 during April 2009. After the executed new issue the share capital is expected to increase with SEK 991,000 to SEK 10,901,570, corresponding to 561,671 A shares and 10,339,899 B shares. After the issue the new shares represent 9.1 % of the capital and 6.2% of the votes.

Sweden - Nyhetsbyr�n Direkt har intervjuat VD Elisabeth Lindner i samband med den publicerade nyheten om fulltecknad riktad emission.

Mon, 21 Apr 2008 10:16:00

DIAMYD MEDICAL: EMISSIONSPENGAR KOMMER IN UNDER VECKAN - VD (Direkt) 2008-04-21 12:09 STOCKHOLM (Direkt) Diamyd Medicals riktade emission till en begr�nsad krets professionella investerare slutf�rdes i fredags. Pengarna kommer in till bolaget under innevarande vecka. Det inneb�r en utsp�dning av aktiekapitalet med 10 procent. L�s hela notisen h�r: http://www.avanza.se/aza/press/news.jsp?n=920287source=Direkt

Canada - Diamyd mentioned in Canadian media after publishing press release on strengthened financial position and executed fully subscribed direct placement.

Mon, 21 Apr 2008 10:10:00

Diamyd Strengthens Financial Position and Executes a Fully Subscribed DirectPlacement
Apr 21, 2008 - 06:45 EST

STOCKHOLM, Sweden, April 21 /CNW/ - Diamyd Medical AB (publ) has decided on, and successfully executed, a direct placement of in total 991,000 series B shares. The shares have been placed with a limited group of professional investors at a price of 73 SEK per share. The issue raises 72.3 MSEK in total for the Company before issue costs. For each issued and paid new share one warrant is received free of charge, which gives the right to subscribe for a series B share at a price of 100 SEK during April 2009. Full use of the issued warrants will generate an additional 99.1 MSEK in proceeds to the Company.

Sweden - Biotech Scandinavia writes about Diamyd.

Mon, 21 Apr 2008 10:05:00

Direction gets Diamyd millions A direct placement earns Diamyd Medical proceeds of more than half a million Swedish crowns. A direct placement of 991,000 class B shares has earned millions for Swedish biopharmaceutical company Diamyd Medical. The shares were made available to a group of investors at SEK 73 per share, raising a total of SEK 72,3 million (USD 12,3 million) before issue costs. Each investor received the same number of warrants as they purchased new share for free. The warrants allow the holder to buy further shares at SEK 100 during April of 2009. Av Ida Persson

Spain - Diamyd mentioned in Spanish media after publishing press release on strengthened financial position and executed fully subscribed direct placement.

Mon, 21 Apr 2008 10:01:00

Diamyd fortalece la posici�n financiera y ejecuta una colocaci�n directa totalmente suscrita ESTOCOLMO, Suecia, April 21 /PRNewswire/ -- Diamyd Medical AB (Estocolmo: DIAMB.ST - noticias) (publ) ha decidido, y ejecutado con xito, una colocaci�n directa de un total de 991.000 acciones de serie B. Las acciones se han colocado con un grupo limitado de inversores profesionales a un precio de 73 coronas suecas por acci�n. La emisi�n asciende a 72,3 millones de coronas suecas en total para la compa��a antes de la deducci�n de costes de emisi�n. Por cada nueva acci�n emitida y pagada se recibe una garant�a sin carga alguna, lo que concede el derecho a suscribir una acci�n de serie B a un precio de 100 coronas suecas durante abril de 2009. El uso completo de las garant�as emitidas generar� 99,1...

Sweden - Nyhetsbyr�n Direkt citerar artikel om Diamyd publicerad i Dagens Industri.

Wed, 16 Apr 2008 11:14:00

Nyhetsbyr�n Direkt citerar en artikel om Diamyd publicerad i Dagens Industri pappersutg�van 16 april 2008. Rubrik fr�n Nyhetsbyr�n Direkt: "NIH INVESTERAR 130-150 MKR I VACCIN" Rubrik i Dagens Industri "MILJONREGN �VER VACCIN MOT DIABETES"

USA - Equities magazine top-analyst Anthony W. Haddad pick Diamyd share as favorite

Tue, 15 Apr 2008 10:31:00

In the latest paper edition of US monthly magazine "Equities", top-analyst Anthony W. Haddad has listed Biotech ADR picks. One pick is Diamyd and the other is Australian based Agenix. - This is great news for us at Diamyd, that Wallstreet's No. 1 analyst has picked our stock from the otcqx ADR list, says Elisabeth Lindner CEO and president at Diamyd Medicals.

Sweden - Artikel om Diamyds kommande studie.

Sat, 12 Apr 2008 13:33:00

Forskarna studerar vaccin mot diabetes Publicerad: 12 april 2008, 01:15 Senast uppdaterad: 12 april 2008, 07:05 Kristianstad Barn och ungdomar med diabetes p� Centralsjukhuset har b�st blodsockerv�rden bland sk�nska diabetiker. Nu startas en ny studie f�r att vaccinera barn mot diabetes. L�s hela artikeln h�r �

Sweden - Webfinanser.com skriver om Diamyds barndiabetesforskning

Sat, 12 Apr 2008 13:28:00

Barndiabetesfonden h�jer utdelningen till 5 miljoner kronor Den svenska studien visar p� positiva resultat och studien ska nu ut�kas till fas III b�de i USA och Sverige. Den svenska studien leds av professor Johnny Ludvigsson vid Universitetssjukhuset i Link�ping. L�s hela artikeln �r:http://www.webfinanser.com/site/artikel.asp?pmid=681028

USA - Research and Markets: What Strategies Will Yield Novel Treatments for Autoimmune Disease Which Now Affects 2-8% of the U.S. Population?

Thu, 10 Apr 2008 11:43:00

Companies Mentioned in report in connection to potential curative therapies on the horizon: cell therapies like stem cell replacement and tolerization vaccines represent potential for cures. Diamyd Medical mentioned. Please read the whole article here: http://www.researchandmarkets.com/reports/c88188

Sweden - DIAMYD MEDICAL: STARTAR FAS III-STUDIE MED DIAMYDVACCINET

Fri, 04 Apr 2008 10:21:00

Dagens Nyheter publicerar nyheter fr�n Nyhetsbyr�n Direkt

USA - Type 1 Diabetes - Diamyd Gets Authorization to Begin Phase III Study in the US

Wed, 02 Apr 2008 13:28:00

US Silobreaker.com writes about Diamyd Phase III trials

Germany - Diamyd erh�lt Zulassung f�r Studie der Phase III in den USA

Wed, 26 Mar 2008 12:33:00

Diamyd Phase III mentioned in german media

USA - Diamyd takes trial to Europe

Thu, 20 Mar 2008 11:18:00

Biotech writes about Diamyd Phase III trials.

France - Diamyd Medical autoris� � lancer des essais cliniques de phase III sur son vaccin contre le diab�te Diamyd� en Europe

Wed, 19 Mar 2008 10:06:00

Diamyd mentioned in french media

Diamyd in Media

Sweden - Dagens Industri listar b�rsnoterade bolag som klarat sig b�ttre �n index under 2008.

Sweden - Svenska Barnl�karf�reningens tidning med tema diabetes.

Sweden - B�rsveckan g�r analys p� Diamyd

Sweden - Veckans Aff�rer skriver under rubriken "K�ptips: Vaccin v�rt miljarder"

Sweden - Veckans Aff�rer listar Diamyd som k�pv�rd aktie

Sweden - Aftonbladet skriver om Louise 17 �r som f�tt Diamyd� vaccinet

USA - Genetic Engineering & Biotechnology News writes about Diamyd sponsored gene therapy for cronic pain study in the US

Sweden - Carl-David Agardh intervju p� Diabetesportalen

Sweden - Samlade notiser fr�n svenska nyhetsbyr�er

Sweden - Biotech Sweden writes about Diamyd.

Sweden - Di.se skriver om bioteknik: "Det finns guldkorn inom biotekniken"

Sweden - Diamyd-aktien listas bland Aff�rsv�rldens l�sarkrets favoritaktie.

Sweden - Nyhetsnotis om Diamyd i Aff�rsv�rlden - Allt g�r enligt plan med fas-III studie

Sweden - Nyhetsnotis om Diamyd i Aff�rsv�rlden - planerar NTDDS-studie fas-I/II under 2009

Sweden - Nyhetsnotis om Diamyd i Aff�rsv�rlden - Ber�knad burnrate 4,5 Mkr per m�n 2008

Sweden - Biotech Scandinavia writes about Diamyd.

Sweden - Aff�rsv�rlden har publicerat flera notiser om Diamyd

USA - The BioWorld Today ranks Diamyd� Monday 18th of August

Sweden - Dagens Industri skriver om starkt �r f�r biotekniksektorn.

Sweden - Vaccinet Diamyd� positioneras i tv� olika produkter; en f�r typ 1-diabetes och en separat produkt f�r LADA. Detta efter att 5-�rs data publiceras.

Sweden - Diamyds VD och koncernchef Elisabeth Lindner intervjuad i Dagens Nyheter Ekonomi m�ndag 7 juli 2008.

Sweden - Dagens Industri skriver om kvinnliga chefer i b�rsbolag. Diamyd ligger i topp.

Sweden - Dagens Medicin har publicerat artikel med Professor Johnny Ludvigsson, huvudpr�vare i Diamyd� fas III europeiska studie.

Sweden - B�ttre chans �n n�gonsin att l�sa diabetesg�tan - Intervju med �ke Lennmark publicerad p� diabetesportalen

USA - Diamyd Medicals CEO Mrs Elisabeth Lindner in webcast interview for World Business Broadcast.

Sweden - Barndiabetesfonden n�mner Diamyds Fas III studie p� sin f�rsta sida

Sweden - Nyhetsnotis om m�jlighet att s�rl�kemedelsklassa Diamyd�

Sweden - Nyhetsnotis om potentiella partnerdiskussioner

Sweden - Nyhetsnotis om Diamyds finansiering

Sweden - Nyhetsnotis om intresse fr�n omv�rlden f�r Diamyd�

Sweden - "Om tre �r kan diabetesvaccinet vara h�r" - skriver Svenska Dagbladet N�ringsliv p� f�rsta sidan.

Sweden - Intervju med Elisabeth Lindner, p� placera.nu "Vi st�r inf�r ett genombrott"

USA - Technology Review writes about Diamyd NTDDS platform

Sweden - Further Boost For Swedish Diabetes Research. Stockholm Business Region Life Science News writes about Diamyd.

USA - BioWorld International publish interview with Diamyd CEO Elisabeth Lindner.

USA - Picture from Times Square, New York, Monday April 21st 2008. Diamyd CEO Elisabeth Lindner.

Germany - Diamyd mentioned in German media after publishing press release on strengthened financial position and executed fully subscribed direct placement.

Sweden - Dagens Industri har noterat Diamyds kvartalsrapport i dagens papperstidning.

Sweden - Diamyd omn�mnt i Dagens Industri pappersbilaga 22 april 2008.

Sweden - DI.se citerar VD-ordet fr�n senaste kvartalsrapporten

France - Diamyd mentioned in French media after publishing press release on strengthened financial position and executed fully subscribed direct placement.

USA - Reuters Significant Developments: Biotechnology

Sweden - Nyhetsbyr�n Direkt har intervjuat VD Elisabeth Lindner i samband med den publicerade nyheten om fulltecknad riktad emission.

Canada - Diamyd mentioned in Canadian media after publishing press release on strengthened financial position and executed fully subscribed direct placement.

Sweden - Biotech Scandinavia writes about Diamyd.

Spain - Diamyd mentioned in Spanish media after publishing press release on strengthened financial position and executed fully subscribed direct placement.

Sweden - Nyhetsbyr�n Direkt citerar artikel om Diamyd publicerad i Dagens Industri.

USA - Equities magazine top-analyst Anthony W. Haddad pick Diamyd share as favorite

Sweden - Artikel om Diamyds kommande studie.

Sweden - Webfinanser.com skriver om Diamyds barndiabetesforskning

USA - Research and Markets: What Strategies Will Yield Novel Treatments for Autoimmune Disease Which Now Affects 2-8% of the U.S. Population?

Sweden - DIAMYD MEDICAL: STARTAR FAS III-STUDIE MED DIAMYDVACCINET

USA - Type 1 Diabetes - Diamyd Gets Authorization to Begin Phase III Study in the US

Germany - Diamyd erh�lt Zulassung f�r Studie der Phase III in den USA

USA - Diamyd takes trial to Europe

France - Diamyd Medical autoris� � lancer des essais cliniques de phase III sur son vaccin contre le diab�te Diamyd� en Europe